Thera-SAbDab

DARATUMUMAB

>   Structural Summary
TherapeuticDaratumumab
TargetCD38
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
100% seqID Fv Structure7dun%3AHL%2F7duo%3AHL%2F7dha%3ACB [Fvs: ]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental TechnologyMedarex HuMAb Mouse
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedBoston Medical Center%3BBristol-Myers Squibb%3BDana-Farber Cancer Institute%3BFrench Innovative Leukemia Organisation%3BGenentech%3BGenmab%3BJanssen Biotech%3BJanssen Research %26 Development%3BM. D. Anderson Cancer Center%3BSyros Pharmaceuticals
Conditions ApprovedMultiple myeloma
Conditions ActiveAmyloid light-chain amyloidosis%3BAcute myeloid leukaemia%3BChronic lymphocytic leukaemia%3BDiffuse large B cell lymphoma%3BFollicular lymphoma%3BMantle-cell lymphoma%3BMyelodysplastic syndromes%3BPrecursor B-cell lymphoblastic leukaemia-lymphoma%3BPrecursor T-cell lymphoblastic leukaemia-lymphoma%3BProstate cancer%3BT-cell lymphoma%3BWaldenstrom%27s macroglobulinaemia%3BSolid tumours
Conditions DiscontinuedNon-small cell lung cancer
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy